Erythromycin estolate

Erythromycin estolate is the Erythromycin (HY-B0220) derivative[1], is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport[2].

Product Specifications

CAS Number

[3521-62-8]

UNSPSC

12352005

Hazard Statement

H302, H317, H334

Target

Aminotransferases (Transaminases) ; Antibiotic; Bacterial; Dengue Virus; Flavivirus

Type

Natural Products

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/erythromycin-estolate.html

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCCOS(=O)(O)=O.CCC(O[C@H]([C@H](C[C@@H](C)O1)N(C)C)[C@]1([H])O[C@@H]2[C@H]([C@@H]([C@H](C(O[C@@H]([C@@](C)(O)[C@H](O)[C@@H](C)C([C@H](C)C[C@]2(O)C)=O)CC)=O)C)O[C@@]3([H])C[C@](C)([C@@H](O)[C@H](C)O3)OC)C)=O

Molecular Formula

C52H97NO18S

Molecular Weight

1056.39

Precautions

H302, H317, H334

References & Citations

[1]Lu X, et al. Integrated systems toxicology approaches identified the possible involvement of ABC transporters pathway in erythromycin estolate-induced liver injury in rat. Food Chem Toxicol. 2014 Mar;65:343-55.|[2]Wang X, et al., Erythromycin Estolate Is a Potent Inhibitor Against HCoV-OC43 by Directly Inactivating the Virus Particle. Front Cell Infect Microbiol. 2022 Jul 7;12:905248.